Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Daniel C RabeKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-6126-2280
Adarsh ChoudhuryKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-3288-9356
Dasol LeeKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0009-5913-8366
Evelyn G LucianiKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0000-8194-6399
Uyen K HoKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0001-8031-1380
Alex E ClarkDepartments of Pathology and Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0003-1687-416X
Jeffrey E GlasgowDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-6699-8983
Sara VeigaKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
William A MichaudDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3664-2094
Diane CapenMicroscopy Core of the Program in Membrane Biology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-7254-788X
Elizabeth A FlynnKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
Nicola HartmannKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0009-0004-6182-8263
Aaron F GarretsonDepartments of Pathology and Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0003-3855-4482
Alona MuzikanskyMassachusetts General Hospital Biostatistics, Harvard Medical School, Boston, MA, USA.
Marcia B GoldbergBroad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-4266-9733
Douglas S KwonRagon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.ORCID 0000-0001-8521-8735
Xu YuDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8295-884X
Aaron F CarlinDepartments of Pathology and Medicine, School of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID 0000-0002-1669-8066
Yves TheriaultQualcomm Institute, University of California, San Diego, La Jolla, CA, USA.ORCID 0009-0003-2784-2590
James A WellsDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-8267-5519
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-2434-4978
Peggy S LaiDepartment of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9501-8606
Sayed Ali RabiDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Anh N Hoang
Genevieve M BolandKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-7522-6173
Shannon L StottKrantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-0349-0522
Funding
The Harvard Clinical and Translational Science CenterUL1TR002541 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2018 to 2022
$93.0M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
RADx-Rad Discoveries & Data: Consortium Coordination Center Program OrganizationU24LM013755 · NLM · YALE UNIVERSITY · PI ARONOFF-SPENCER, ELIAH S, OHNO-MACHADO, LUCILA · 2021 to 2023
$23.3M
P&F programP30DK135043 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Dennis Brown · 2023 to 2026
$5.4M
Benchmarking the Sensitivity and Specificity of the Herringbone Microfluidic Device for Rare Particle CaptureR01CA226871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHED, BRIAN VALA, STOTT, SHANNON L · 2018 to 2023
$2.3M
Microfluidic Isolation and Characterization of SARS-CoV-2 and Virus Related ExosomesU18TR003793 · NCATS · MASSACHUSETTS GENERAL HOSPITAL · PI BOLAND, GENEVIEVE MARIE, STOTT, SHANNON L · 2021 to 2022
$2.0M
The role of extracellular vesicles in regulating response to immunotherapyF32CA236417 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI RABE, DANIEL CHRISTOPHER · 2020 to 2022
Measuring virus in biofluids is complicated by confounding biomolecules coisolated with viral nucleic acids. To address this, we developed an affinity-based microfluidic device for specific capture of intact severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our approach used an engineered angiotensin-converting enzyme 2 to capture intact virus from plasma and other complex biofluids. Our device leverages a staggered herringbone pattern, nanoparticle surface coating, and processing conditions to achieve detection of as few as 3 viral copies per milliliter. We further validated our microfluidic assay on 103 plasma, 36 saliva, and 29 stool samples collected from unique patients with COVID-19, showing SARS-CoV-2 detection in 72% of plasma samples. Longitudinal monitoring in the plasma revealed our device's capacity for ultrasensitive detection of active viral infections over time. Our technology can be adapted to target other viruses using relevant cell entry molecules for affinity capture. This versatility underscores the potential for widespread application in viral load monitoring and disease management.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Ultrasensitive detection of intact SARS-CoV-2 particles in complex biofluids using microfluidic affinity capture. · full record | OpenQuestion